|
|
5000 Shoreline Ct., Suite 200
South San Francisco, CA 94080 USA
phone:650-624-6900
fax:650-589-1501
|
|
| Symbol |
CTRX |
| Exchange |
|
| Founded |
2000 |
| Employees |
|
|
|
| www.cotherix.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Biopharmaceutical company with a clinical program for pulmonary hypertension. |
|
| Management |
| Scott Harkonen, Chairman & CEO;Donald Santel, Pres. & COO; Benson Fong, VP, Acting CFO |
| |
|
|
|
|
|
|
| Recent Results |
| The CoTherix management team demonstrated that they have experience and knowledge of the market to make Ventavis a success in the U.S. Having obtained EU approval the Company looks forward to working with CoTherix to seek regulatory approval for Ventavis in the United States. |
| |
|
|
|
|
| Keywords |
| Ventavis, pulmonary hypertension, heart failure, nebulizer, prostacylin, scleroderma, lupus, idiopathic pulmonary fibrosis, |
|
|
|
| Description |
|
CoTherix, Inc., (formerly known as Exhale Therapeutics, Inc.) is a privately held specialty biopharmaceutical company with a clinical program for pulmonary hypertension. CoTherix was founded in February 2000 by Gerard Turino, MD, past president of the American Thoracic Society, and Jerome Cantor, MD, a leading pulmonary pathologist. |
|
| Products / Services |
Ventavis is the only prostacyclin product that targets the pulmonary vessels directly by inhalation. A recent European Phase 3 trial comparing Ventavis to placebo achieved the study's primary endpoint, improvement in exercise capacity and functional class for patients with primary pulmonary hypertension NYHA class III affected by severe symptoms and heart failure. Also in development is ETX-100 (hyaluronic acid solution for nebulization) for the treatment of emphysema due to cigarette smoking or alpha 1 antitrypsin (AAT) deficiency. The compound has been well tolerated to date in Phase I trials in normal volunteers and in patients with AAT deficiency. An orphan product designation has been obtained.
|
|
| Technology / Differentiation |
| The Company's lead compound is Ventavis (iloprost inhalation solution) for the treatment of primary pulmonary hypertension, a life-threatening elevation of pressures in the pulmonary circulation that severely compromises heart function. Iloprost is a prostacyclin given by inhalation using a nebulizer. Ventavis is the only prostacyclin product that targets the pulmonary vessels directly by inhalation. |
|
| Market / Customers |
Pulmonary hypertension is a life-threatening disease of the blood vessels in the lung in which the pressure in the pulmonary artery is significantly higher than normal. Approximately 50,000 Americans are affected with either primary pulmonary hypertension (no known underlying cause) or secondary pulmonary hypertension that results from diseases such as scleroderma, lupus or idiopathic pulmonary fibrosis. Ventavis was approved in Europe in September 2003 and will be marketed there by Schering AG. CoTherix will meet with U.S. Food and Drug Administration before the end of the year to discuss steps required for approval in the United States.
|
|
| Strategy |
Acquiring late-stage compounds and developing them through approval and commercialization.
|
|
| Funding |
| The Company announced that it closed a $55 million placement of Series C Preferred Stock. The proceeds of the fundraising will finance the development of Ventavis and acquisition and development of other late-stage products. Investors include Alta Partners, BioAsia Investments, Frazier Healthcare Ventures, MPM Capital, Sofinnova Ventures, Sofinnova Partners, Spray Venture Partners and Thomas Weisel Healthcare Ventures. |
|
| Status |
| CoTherix, Inc., has acquired exclusive United States development and marketing rights to Ventavis (iloprost), a synthetic prostacyclin analogue for the treatment of primary pulmonary hypertension developed by Schering AG. Ventavis was approved last month by the European Commission for marketing in all EU countries for the treatment of Primary Pulmonary Hypertension NYHA class III. Schering plans to start marketing Ventavis this year and to roll-out the product across Europe in 2004. CoTherix executives plan to meet with U.S. Food and Drug Administration before the end of the year to discuss steps required for approval in the United States. |
|
|
|
| |
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
